Halozyme Therapeutics Inc. Common Stock vs NXP Semiconductors N.V. Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while NXP Semiconductors N.V. Common Stock trades at $227.52 (market cap $58.27B). The key difference: NXP Semiconductors N.V. Common Stock is far larger — about 4.6× Halozyme Therapeutics Inc. Common Stock's market cap, and NXP Semiconductors N.V. Common Stock pays a 1.76% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and NXP Semiconductors N.V. Common Stock for 0 Days on average.
| HALO | NXPI | |
|---|---|---|
Market Cap | $12.58B | $58.27B |
Volume | 2,179,278 | 3,950,702 |
Sector | Health | Technology |
52-Week High | $115.22 | $332.67 |
52-Week Low | $61.63 | $184.19 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $14.49B | $66.38B |
Dividend Yield | — | 1.76% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →NXP Semiconductors designs semiconductor solutions for embedded applications. Its products serve automotive, industrial and IoT, mobile, and communications-infrastructure markets.
Read more on NXPI →